Probatebeta
Drug

Droxidopa

As of the edition of 20 October 2026, Droxidopa is a small molecule: marketed, first approved in 2014 (US); acts on ADRA1A, ADRA1B and ADRA1D and 6 more; no US protection is listed.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 2014
Kind
Small molecule
Brand name
Northera
First approved
18 February 2014 (US)
Approvals on record
3 in 1 region
Holder of the most recent approval
Lundbeck
Registered trials
31, 9 stopped early
Disease areas
Nervous system; Heart and blood vessels; Bones, joints and muscles; Inherited and neonatal; Injuries; Mental health

US protection

No US protection is listed.

The FDA registers list no drug-substance patent or exclusivity that counts for this drug.

This is the US only.

Companies that need a new molecule because of this drug

3 company-target rows on route B because of this drug.

Companies on route B for this drug

In the product

3 company-target rows are on route B because of Droxidopa.

See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.

Targets

GeneProteinUniProt
ADRB2Beta-2 adrenergic receptorP07550
ADRB1Beta-1 adrenergic receptorP08588
ADRA2AAlpha-2A adrenergic receptorP08913
ADRB3Beta-3 adrenergic receptorP13945
ADRA2BAlpha-2B adrenergic receptorP18089
ADRA2CAlpha-2C adrenergic receptorP18825
ADRA1DAlpha-1D adrenergic receptorP25100
ADRA1AAlpha-1A adrenergic receptorP35348
ADRA1BAlpha-1B adrenergic receptorP35368

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase not stated3200
Phase 14211
Phase 213236
Phase 36402
Phase 45500
All trials31

Who has held its approvals

CompanyRoleYears
LundbeckOriginator and Lead sponsor of trials2008 to now

Other drugs at ADRB2

All of ADRB2

Other marketed drugs held by Lundbeck

Lundbeck